Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ic open, multi-centre clinical trial for Proxalutamide in combination with Exemestane, Letrozole and Fulvestrant for patients with metastatic breast cancer

Next Previous
Trial Profile

Phase Ic open, multi-centre clinical trial for Proxalutamide in combination with Exemestane, Letrozole and Fulvestrant for patients with metastatic breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Pruxelutamide (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions
  • Sponsors Suzhou Kintor Pharmaceuticals

Most Recent Events

  • 24 Oct 2023 Results (n=37; Between June 18, 2019 and Sep 5, 2022) assessing the safety, efficacy and pharmacokinetics of proxalutamide, in combination with endocrine therapies in hormone-receptor+/human epidermal growth factor receptor 2-/AR+ metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.
  • 28 Aug 2023 According to a Kintor Pharmaceuticals media release, data from this study will be presented at ESMO 2023
  • 25 Mar 2022 According to a Kintor Pharmaceuticals media release, the company has completed patient enrollment on 25 August 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top